[CAS NO. 324022-08-4] EBNA1-IN-SC7
PRODUCTS SPECIFICATIONS [324022-08-4]
DESCRIPTION [324022-08-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 462.31 |
| Molecular Formula | C20H16BrNO5S |
| SMILES | CC(N(C1=CC=C(OC(C)=O)C(Br)=C1)S(=O)(C2=CC=C3C=CC=CC3=C2)=O)=O |
Summary
In Vitro
EBNA1-IN-SC7 (compound SC7) (5 µM) can completely block transcriptional activation of EBNA1 and show a 60% inhibition of Zta (EBV-encoded b-zip DNA binding protein) trans-activation in HEK293T cells
[2]
.
EBNA1-IN-SC7 (compound SC7) (10 µM, 6 days) has no significant effect on EBV genome copy number of Raji Burkitt lymphoma cells
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
References
- [1] Lijun Jiang, et al. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers. Theranostics. 2018 Oct 22;8(19):5307-5319.
- [2] Ning Li, et al. Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One. 2010 Apr 12;5(4):e10126.